Physician profile
Robert Hines Mitchell
NPI 1952721086
$910.65
in general payments reported to CMS, 2019-2025
16 companies · $137 in 2025
The $137 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.09 · 2021: $144 · 2022: $174 · 2023: $188 · 2024: $192 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $516.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $226.17 | 2022-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $164.83 | 2021-2023 | |
| Abbvie INC. | $96.83 | 2022-2025 | |
| La Jolla Pharmaceutical Company | $84.13 | 2022-2023 | Xerava |
| Boston Scientific Corporation | $58.83 | 2023-2024 | Watchman Flx |
| Pfizer INC. | $53.70 | 2024 | |
| Janssen Pharmaceuticals, INC | $34.25 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $32.74 | 2021-2023 | Farxiga |
| Mylan Specialty L.P. | $24.85 | 2024 | Yupelri |
| Paratek Pharmaceuticals, INC. | $22.96 | 2025 | Nuzyra |
| Glaxosmithkline, LLC. | $22.29 | 2019 | |
| Portola Pharmaceuticals, LLC | $20.58 | 2019 | |
| Novo Nordisk INC | $19.65 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.81 | 2019 | |
| Allergan, INC. | $16.41 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Enterra Medical, INC. | $15.62 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.